Reducing Amiodarone DYRK1B-Mediated Toxicity Through Minimal Halogen Substitution

Read full text Summarise with VIRAT
Authors: Andrés Sebastián Pirolo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Description / Abstract Amiodarone is the most effective antiarrhythmic drug available for life-threatening ventricular arrhythmias, with no equivalent therapeutic alternative. Yet its chronic use produces severe toxicity in 15-40% of patients, including pulmonary toxicity, thyroid dysfunction, and hepatotoxicity. These adverse effects are the primary limitation of a drug that otherwise saves lives. The molecular mechanism of this toxicity has been partially attributed to off-target inhibition of DYRK1B (Dual-specificity Tyrosine-Regulated Kinase 1B). We apply the Fenlix Motor—a validated Fibonacci-Axial SO(3) docking pipeline—to the problem of toxicity reduction through negative design and minimal structural modification. Screening structural analogues against DYRK1B (on-target toxicity) and DYRK1A (off-target to preserve), we identify A01_2Br—amiodarone with both iodines replaced by bromines—as the top candidate. A01_2Br achieves 1.23× reduced DYRK1B affinity relative to amiodarone while maintaining an identical DYRK1A safety profile. The structural basis is purely geometric: iodine (Van der Waals radius 1.98 Å) creates tighter hydrophobic contacts in the DYRK1B pocket than bromine (1.85 Å). A 0.13 Å difference per halogen, replicated at two symmetric positions, reduces DYRK1B binding without altering the benzofuranone core responsible for antiarrhythmic efficacy. A01_2Br retains the complete pharmacophore of amiodarone, differing by only two atoms. Statement on Intellectual Property and Open Science: The chemical structure, SMILES coordinates, and binding rationale for A01_2Br are disclosed herein to establish formal Prior Art, intentionally preventing restrictive "Composition of Matter" patenting by private entities. This computational proof-of-concept is released to the public domain to enable unrestricted in vitro synthesis and clinical evaluation by the global scientific community, aiming to provide a safer antiarrhythmic alternative without the barrier of intellectual property monopolies.

Fields of Study & Subjects

Computational Drug Discovery Methods Cardiac electrophysiology and arrhythmias Protein Degradation and Inhibitors

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN
Document type
Preprint